Figure 2个  Table 3个
    • Characteristic Number
      gender Male 237
      Female 7
      Age < 30 107
      30–50 103
      > 50 31
      Unknown 3
      Risk factor MSM 186
      Heterosexual 52
      Unknown 6
      On HAART Yes 117
      No 127
      Drug duration 0–6 months 98
      6–12 months 11
      > 12 months 8
      Successfully sequenced Drug treated 20
      Drug naive 100
      Subtype CRF01_AE 78
      B 1
      C 2
      CRF07_BC 25
      CRF08_BC 1
      URF 13

      Table 1.  Characteristics of all study participants in Suzhou, China

    • Mutation Type Mutation Distribution
      CRF01_AE CRF07_BC URFs
      PI Other L10I 1 – –
      L10V 2 – 1
      V11I 1 – –
      K20I 1 – –
      A71V – 6 –
      A71T 1 – 1
      Accessory L33F 1 – –
      Major L76V 1 – –
      RTI Other V90I – 1 –
      V106I 1 – –
      NRTI K70N – – 1
      K70E 1 – –
      NNRTI V179D 4 1 –
      V179E 1 – 2

      Table 2.  Transmitted drug resistance mutations profile in drug-naïve subjects

    • Patient ID Drug Resistance Mutations Regimen Treatment Duration(months) ART start date Sample date Viral load (date) Predicted Phenotypes
      NRTI NNRTI NRTI NNRTI
      AZT 3TC TDF EFV NVP
      CNSZ12 D67N\M184V K101E\G190A 3TC+AZT+NVP 20 2011/12/3 2013/8/22 1.1*105(2013/10/21);1.3*105(2013/11/22) S H S H H
      CNSZ16 M184V Y181I 3TC+TDF+NVP 10 2012/10/20 2013/8/28 4*104(2013/11/12); 3.9*105(2013/12/20) 1.2*105(2014/1/21); 6.6*105(2014/2/21) S H S I H
      CNSZ28 K65R\Y115F\M184V L100I\K103E 3TC+EFV+TDF 2 2015/10/8 2015/12/3 3.14*104(2015/8/21) Undetectable(2016/10.18) S H H H H
      CNSZ32 M184V V106M\G190A 3TC+EFV+TDF 3 2015/10/10 2016/1/13 1.49*105(2015/7/27) S H S H H
      CNSZ70 M41L\E44D\D67N\M184V\T215Y K101H\G190A\N348I 3TC+AZT+NVP 48 2011/7/1 2015/8/25 5.52*102(2015/9/4); 8.55*103(2015/11/30) H H L I H
      CNSZ83 K65R V106M\V179D 3TC+EFV+TDF 3 2015/9/9 2015/12/2 <5.0*102(2015/9/25); 3*105(2016/8/16) S I H H H
      CNSZ128 M184V V106M\V179E 3TC+EFV+TDF 1 2015/11/9 2015/12/7 <5.0*102(2015/10/16);5.55*102(2016/2/22) <5 *102(2016/4/8) S H S H H
      CNSZ134 Y188L 3TC+EFV+TDF 1 2015/11/11 2015/12/9 3.4*105(2015/12/18) S S S H H
      CNSZ149 D67N\K70E\M184V V106M\V179D 3TC+EFV+TDF 11 2015/2/9 2016/1/7 1.5*105(2015/10/18); 2.8*105(2016/1/11) S H L H H
      CNSZ161 T69N\M184I V90I\K103N\V106I\M230L 3TC+EFV+TDF 3 2015/9/30 2016/1/5 1.6*105(2015/8/21); 5.2*104(2015/10/30) 6.4*105(2016/1/29); 6.6*104(2016/9/13) S H S H H
      CNSZ235 D67N\M184V V106M\V179D 3TC+AZT+EFV 3TC+TDF+EFV 16 2014/10/28 2016/3/28 2.1*105(2015/10/27); 2.8*104(2016/1/19) S H S H H
      CNSZ265 M184V V106M\V179D 3TC+TDF+EFV 8 2015/8/19 2016/4/20 6.3*102(2015/8/21); 7.1*105(2016/7/26) S H S H H
      CNSZ365 D67N\K70R\M184V V106M\G190A\F227V 3TC+TDF+EFV 13 2015/7/1 2016/8/26 2.6*105(2016/6/7); 5.0*105(2016/8/19) S H L H H

      Table 3.  Acquired drug resistance mutations in treated subjects and the predicted phenotypes to NRTIs and NNRTIs